24F4A (BIIB059), a monoclonal antibody targeting Blood dendritic cell antigen 2 (BDCA2), is pDC specific therapy currently being evaluated in phase II clinical trials for CLE and SLE (NCT02847598). This evidence concerns the gene CLEC4C and systemic lupus erythematosus.